ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BHC vs DYN // FREE CASH FLOW YIELD

Bausch Health Companies Inc. (NYSE) VS. Dyne Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BHC 5 — DYN 0
▲ FREE CASH FLOW YIELD LEADER: BHC
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BHC VS. DYN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BHC DYN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 7.60% -35.00% +42.60 BHC /roic <GO>
EV/EBITDA & P/E Valuation 10.5x — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE 22.00% -12.73% +34.73 BHC /fcf-yield <GO>
Operating Margin 17.70% — — TIE /operating-margins <GO>
Net Profit Margin 1.50% — — TIE /net-margins <GO>
Revenue Growth (YoY) 6.70% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.45 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 9/9 1/9 +8.00 BHC /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 76.7 50.0 +26.75 BHC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.97 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 19.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.33B $3.18B $152.6M BHC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BHC REV DYN REV BHC GROSS % DYN GROSS % BHC FCF DYN FCF
FY 2025 $10.27B $0 — — $1.00B -$405.1M
FY 2024 $9.63B $0 — — $1.26B -$294.7M
FY 2023 $8.76B $0 — — $637.9M -$188.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BHC // BETA 0.97
DYN // BETA —